Navigation Links
Cylex Announces Valuable Personnel Additions
Date:3/16/2010

COLUMBIA, Md., March 16 /PRNewswire/ -- Cylex™, a global life science company that develops and manufactures in vitro diagnostic products based on patented technology, announced today the expansion of its growing staff with the hiring of Chari-Beth White, Marc Mendels and Julie Fudoli as well as the promotion of James E. "Jim" Brosius.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100112/NE34738LOGO )

"Due to the Company's rapid business development and growth in 2009, we are pleased to announce expansion of our presence throughout North America and abroad. In order to meet our infrastructure development goals, we are extremely pleased that these talented individuals are now with Cylex," said Jack Kromar, Vice President, Sales and Marketing.

Chari Beth White brings significant experience to Cylex as National Sales Manager – over 18 years of progressive sales/marketing and management experience with several major U.S. biotechnology research and pharmaceutical corporations including Gilead Sciences, Inc., Agouron Pharmaceuticals, Pharmacia & Upjohn, and Schering-Plough Pharmaceuticals. Chari Beth will assume responsibility for the direct management and leadership of field-based Business Development Managers. She will deliver sales and market share objectives, develop and execute the Cylex sales plan, and assist by providing solutions that meet customer needs.

Marc Mendels begins his role of Medical Science Liaison (MSL) and comes with extensive experience as a Senior MSL from Astellas and Wyeth Pharmaceuticals, over 16 years of experience in the transplant market, and sales experience from Schering-Plough and Johnson & Johnson. As an MSL, Marc will be a field-based member of the Medical Affairs support team responsible for the application of scientific knowledge and experience to organize the collection of and to analyze clinical data; educate physicians and transplant coordinators; and to establish and maintain clinical/scientific relationships with key opinion leaders, researchers, transplant coordinators, laboratory managers, and other members of the scientific community.

Julie Fudoli joins Cylex as a Business Development Manager, and has over 14 years of experience in sales and sales management. She successfully developed and managed the CVS/Caremark transplant team as the National Transplant Manager for CVS/Caremark and has also been involved with the transplant community as the National Board Treasurer of the Transplant Recipient International Organization (TRIO) and a member of the National Foundation for Transplant (NFT). Julie will continue to build strong business relationships with clinical decision makers and the consumers of our products.

"These individuals further strengthen the Sales and Medical Affairs teams at Cylex, and also complement the newly created position, Manager, International Sales and Marketing filled by recently promoted Jim Brosius," added Kromar.

James ("Jim") E. Brosius was promoted to International Manager, Sales and Marketing and will focus on and grow Cylex international business, since Cylex continues to see increasing interest and demand in international markets for ImmuKnow. Jim has a thorough understanding of the value of ImmuKnow in transplantation, a significant depth of knowledge within the transplant field, and a demonstrated ability to communicate and build relationships with key opinion leaders and clinicians. Jim's focus on our international opportunities will accelerate Cylex's ability to increase the global use and sales of ImmuKnow.

According to Kromar, "Today marks another very exciting moment at Cylex. The growth that we experienced both within our sales and staff expansion has catapulted us within the transplant market. Each of our new and promoted employees dramatically enhances our ability to foster continued innovation and business development in transplantation."

About Cylex, Inc.

Cylex is a privately held global life science company that is the leader in the development and manufacture of in vitro diagnostic products. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The company is based in Columbia, MD USA. For more information, visit www.cylex.net.

About ImmuKnow

ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. For more information, visit www.cylex.net.

SOURCE Cylex, Inc.

Back to top

RELATED LINKS
http://www.cylex.net

'/>"/>

SOURCE Cylex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
2. Cylex Announces Brad L. Stewart as President of the Company
3. Cylex(TM) Receives ISO 13485:2003 and 9001:2000 Quality Certifications
4. Cylex, Inc. Appoints Brad L. Stewart as Chief Executive Officer and Chairman of the Board
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)...   iSpecimen ®, the marketplace for ... Service (DPS), a full-service anatomic pathology reference lab ... States , has joined a program offered by ... (DHIN) to make human biospecimens and associated data available ... announced in 2015 as a collaboration between iSpecimen and ...
(Date:3/22/2017)... 22, 2017 MarketNewsUpdates.com News Commentary  ... The traditional ... being pressured as of late due to the rise of ... has a dramatic impact on patient,s quality of life as ... for identifying new forms of opioid formulations that prevent abuse. ...
(Date:3/22/2017)... Mass. , March 22, 2017   Boston ... next-generation cancer therapeutics designed to target cancer stemness pathways, ... Patricia S. Andrews as Chief Executive Officer, effective ... succeed Chiang J. Li , M.D., FACP, who ... ten years ago. Under his leadership, Boston Biomedical has ...
(Date:3/22/2017)... ... March 21, 2017 , ... Premier executive recruitment firm, Slone Partners, is ... by Hunt Scanlon Media. , Hunt Scanlon Media is one of the ... global news source in the human capital sector. , “It is a great honor ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , ... software globally, announces significant enhancements to new and core ... 2016. New products include mobile and desktop Acuant FRM ... TM - a real time manual review of ... idScan® technology provides the fastest and most accurate capture ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):